KRAS and pancreatic intraductal papillary-mucinous neoplasm: The genomic landscape of IPMNs has been steadily cataloged over the past decade, and has identified both early drivers that predominate in low-grade (LG) IPMNs, such as KRAS, GNAS, and RNF43 mutations, as well as drivers associated with IPMN progression, including TP53, PIK3CA, and SMAD4, among others (5).